Haloperidol Tablets

Haloperidol Tablets

Form: Tablets

Strength: 0.5 mg, 1 mg, 2 mg, 5 mg, 10 mg, 20 mg

Reference Brands: Haldol®(US)

Category: Antipsychotropic Drugs

Haloperidol tablets are FDA-approved in the United States for treating schizophrenia, acute psychosis, and Tourette’s syndrome. In the European Union, they are authorized in various member states under national or decentralized procedures for similar psychiatric conditions. Regulatory submissions must meet GMP standards, include bioequivalence data, and provide robust safety documentation addressing risks like QT prolongation, extrapyramidal symptoms, and neuroleptic malignant syndrome. U.S. labeling must comply with FDA boxed warning requirements. EU filings must include Risk Management Plans (RMPs) and pharmacovigilance systems. To explore dossier-ready Haloperidol tablets and other forms, visit Pharmatradz.com — your trusted B2B pharmaceutical partner.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Risperidone Long-Acting Injection

Strength: 12.5 mg, 25 mg, 37.5 mg, 50 mg vials/syringes

Form: Long-Acting Injection

Reference Brands: Risperdal Consta(US &EU)

View Details Get Enquiry
Zuclopenthixol ong-acting IM Injection (Depot)

Strength: 200 mg/mL, 500 mg/mL

Form: Long-acting IM Injection (Depot)

Reference Brands: Clopixol Depot®(US)

View Details Get Enquiry
Zuclopenthixol Short-acting Intramuscular Injection

Strength: 50 mg/mL

Form: Short-acting Intramuscular Injection

Reference Brands: Clopixol-Acuphase®

View Details Get Enquiry
Zuclopenthixol tablets

Strength: 10 mg, 25 mg, 40 mg

Form: Oral Tablets

Reference Brands: Clopixol®(EU)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

We use cookies to ensure you get the best experience. Learn more